SpyGlass Pharma opened higher at $35.68, compared with its previous close of $34.97. In the last trading session, the stock traded between $33.43 and $35.68. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 1 year ago in SpyGlass Pharma is now worth
$ 126.91
Giving a profit of
$ 26.91 (26.91%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.47 (-4.19%)
Day High
$35.68
Day Low
$33.43
Day Open
$35.68
Prev Close
$34.97
Volume
44,558
1W Return
-2.59%
1M Return
34.41%
3M Return
34.99%
6M Return
41.01%
1Y Return
26.91%
Fundamentals
Market Cap ($ Mn)
-
PE Ratio
-
PB Ratio
3.80
PEG Ratio
-
ROE
-
ROCE
-53.01%
EPS (TTM)
-
Investment Returns
1 Week
-2.59%
1 Month
34.41%
3 Months
34.99%
6 Months
41.01%
9 Months
21.62%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
Updates
12Nov
HC Wainwright maintains Buy on SpyGlass Pharma, lifts price target to $43
HC Wainwright & Co. maintains Buy rating on SpyGlass Pharma. Price target raised from $37 to $43 by analyst Yi Chen. Target increase amounts to $6 per share.
Today
12Nov
SpyGlass Pharma Q3FY27 Results: Net loss $24.3m, acquires AVS for IOL capacity
Net loss stood at $24.3 million ($0.73/share) for Q3 2026, missing consensus estimate of $0.63/share. Acquired Advanced Vision Science for ~$13 million to secure IOL manufacturing capacity. Four-year FIH data for BIM-IOL System showed 37% mean IOP reduction and 86% drop-free patients. Cash position of $215.8 million expected to fund operations through 2028.
Yesterday
19Oct
SpyGlass Pharma BIM-IOL trial cuts eye pressure by 37% over four years
Mean IOP reduced by 37% across all three dose cohorts in the four-year interim analysis. 86% of evaluable patients remained off all topical IOP-lowering drops throughout the study period. 90% of participants maintained best-corrected distance visual acuity of ≥20/25. No product-related adverse events were reported in the 21-patient evaluable cohort.
